L’adénosine est une molécule dotée d’un fort potentiel thérapeutique, mais présentant néanmoins un temps de demi-vie plasmatique extrêmement court qui limite de manière sérieuse son efficacité. Comme présenté dans l’introduction bibliographique de cette thèse, cette difficulté peut être surmontée grâce à l’utilisation de systèmes de délivrance de médicaments à base de lipides. L’adénosine peut en effet être soit encapsulée dans des liposomes, soit simplement couplée à un lipide. Parmi les « lipidizations » de l’adénosine, la « squalénisation », notamment, a favorablement modifié la biodistribution de cette substance active. Cette technique consiste à coupler l’adénosine à une molécule lipophile dérivée du squalène, générant ainsi des bioconjugués ayant la capacité de s’auto-assembler spontanément en milieu aqueux sous forme de nanoparticules d’une centaine de nanomètres de diamètre. L’injection de ces nanoparticules d’adénosine-squalène (AdSQ) par voie intraveineuse a donné des résultats très prometteurs pour le traitement de l’ischémie cérébrale et du traumatisme de la moëlle épinière. Ainsi, l’objectif de cette thèse a consisté à faire progresser le développement pré-clinique de ces nanomédicaments suivant deux axes principaux: l’étude du mécanisme d’action et l’amélioration de la formulation.De ce fait, le premier chapitre de cette thèse présente les résultats obtenus lors de l’étude in vitro du mécanisme d’action des nanoparticules d’AdSQ. Les travaux ont montré que ces nanoparticules d’AdSQ n’interagissaient pas directement avec les récepteurs à l’adénosine, mais formaient un réservoir intracellulaire d’adénosine. En effet, après internalisation, le bioconjugué d’AdSQ est clivé pour libérer l’adénosine. Celle-ci finit par être effluée par les cellules vers le milieu extracellulaire, où elle peut ainsi activer les récepteurs spécifiques situés au niveau des membranes des cellules avoisinantes. Après étude du mécanisme, l’amélioration de la formulation de ces nanoparticules a été explorée et décrite dans le deuxième chapitre. Les efforts ont été principalement concentrés sur la lyophilisation de la suspension nanoparticulaire, afin de proposer une formulation stable dans le temps et facile d’utilisation dans le cadre médical. Les conditions utilisées ont abouti au bon maintien des propriétés physico-chimiques des nanoparticules et l’obtention de solutions injectables sans risque chez l’animal. Dans son ensemble, ce travail de thèse a permis d’élargir les perspectives d’application des nanoparticules d’AdSQ grâce à une meilleure compréhension de leur mécanisme d’action ainsi que la mise au point d’une formulation plus adaptée aux besoins cliniques. / Adenosine has a high therapeutic potential but its extremely short half-life in blood seriously impairs its efficacy. As presented in the literature review, this difficulty can be overcome by using lipid-based drug delivery systems. Indeed, adenosine can be encapsulated into liposomes or conjugated to a lipid. In particular, among adenosine « lipidizations », the so-called « squalenoylation » has been shown to enhance adenosine biodistribution. This technique consists in coupling adenosine to a lipophilic squalene derivative, thus generating bioconjugates which are able to spontaneously self-assemble as nanoparticles of 100 nm of diameter in aqueous solution. Intravenous injection of these squalene-adenosine (SQAd) nanoparticles led to highly promising results for the treatment of cerebral ischemia and spinal cord injury. Thus, the aim of this thesis was to push forward the pre-clinical development of these nanomedicines following two main directions: unveiling their mechanism of action and enhancing their formulation.Thereby, the first chapter of this thesis presents the results from in vitro study on SQAd nanoparticles mechanism of action. This work has shown that SQAd nanoparticles did not interact directly with adenosine receptors, but formed an intracellular reservoir of adenosine. Indeed, after internalisation, SQAd bioconjugates acted as prodrugs by releasing free adenosine. This molecule was then efflued out of the cells into the extracellular medium, where it could activate specific membrane receptors on neighbouring cells. After studying the mechanism of action, we explored how to optimize the formulation. Results are described in the second chapter. We focus our efforts on freeze-drying the nanoparticles suspension, in order to offer a stable and easy-to-use formulation. Pre-formulation studies were conducted in order to define the optimal conditions for the preservation of nanoparticles physico-chemical properties and for an easy reconstitution of these nanoparticles suspension which can thus be safely injected intravenously. Overall, this work has widen the field of applications for SQAd nanoparticles thanks to a better understanding of their mechanism of action and the development of a formulation which is more suited to clinical needs.

L’adénosine extracellulaire appartient à la voie de signalisation purinergique et réguledivers processus physiologiques à travers l’activation de ses récepteurs spécifiques (adora).La disponibilité de cette purine dans l’espace extracellulaire est régulée par plusieurs ectoenzymesassurant sa production ou sa dégradation, mais également par des transporteurs denucléosides permettant son passage à travers la membrane. Chez l’adulte, le rôle del’adénosine est assez bien connu. Cependant, l’implication de cette purine au cours del’embryogenèse reste très peu étudiée. Pourtant, un excès d’adénosine dans les phasesprécoces du développement est létal chez la souris et l’oursin, démontrant l’importance de larégulation des concentrations de cette molécule de signalisation lors de l’embryogénèse. Lebut de ma thèse est de comprendre le rôle de l’adénosine au cours de l’embryogenèse enutilisant l’amphibien xénope. En effet, ce modèle a permis de mettre en évidence in vivol’implication de l’ADP au cours du développement de l’oeil chez les vertébrés. La premièrepartie de ce projet a permis de caractériser les acteurs de la voie de signalisation del’adénosine chez le xénope afin d’établir la première carte comparative de leur profild’expression embryonnaire. Cette partie a également permis de mettre en avant laphosphatase alcaline alpl pour son profil d’expression particulier, dans le rein et la rétine. Laseconde partie s’est focalisée sur l’étude fonctionnelle de cette enzyme. Les expériences deperte de fonction montrent son implication lors de la formation de ces deux tissus. / Extracellular adenosine belongs to the purinergic signalling pathway and regulatesvarious physiological processes through activation of specific receptors named adora. Theextracellular concentration of adenosine is regulated by several ecto-enzymes involved eitherin its generation or in its degradation but also by nucleoside transporters enabling its exitoutside or entry inside the cell. In adults, the functions of adenosine are quite well known,however, the its involvement during embryogenesis remains poorly studied. An excess ofadenosine in early phases of development is lethal in mouse and sea urchins, demonstratingthe importance of the extracellular adenosine level regulation during embryogenesis. The aimof my phD is to understand the role of adenosine during embryogenesis using Xenopus as avertebrate model. Indeed, the first in vivo evidence of the implication of the purinergic signallingpathway during vertebrate development, and in particular of ADP during eye formation hasbeen demonstrated using this model. The first part of this project was to characterize all theadenosine signalling pathway actors in Xenopus in order to generate the first comprehensiveand comparative embryonic expression map of these genes. This work allowed me to selectthe alkaline phosphatase alpl for functional studies based on its specific expression profile, inthe retina and kidney. These functional studies, mostly carried out by knockdown experiments,constituted the second part of this phD and showed the implication of this enzyme during theeye and kidney development.

Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmacology and Toxicology Candidate: Magdaléna Svobodová Supervisor: Assoc. Prof. Přemysl Mladěnka, Ph.D. Assoc. Prof. Maria da Glória Correia da Silva Queiroz, Ph.D. Title of diploma thesis: Microglia control adenosine A2A-receptor mediated astrogliosis In the central nervous system, astrocytes and microglia are the main cells coordinating the inflammatory response. During inflammation, dying or temporarily damaged cells release ATP, as a danger-associated signal molecule, that contributes to the induction of astrogliosis and promotes clearance of the debris by immune cells such as microglia. Adenosine that results from ATP metabolism also stimulates astrogliosis. However, the effects of adenosine on astrogliosis may be more complex, since it also modulates microglia phenotype and microglia have been shown to prevent excessive astroglial proliferation mediated by nucleotides. In this context, ATP and adenosine are assumed as relevant signalling molecules in the control of astrogliosis and its modulation by microglia. However, it is still unknown whether and how microglia modulate adenosine-mediated astrogliosis. The present study aims to clarify the impact of microglia in the control of adenosine-induced astrogliosis. Two...

The release of chemical transmitter from nerve terminals is critically dependent on a transient increase in intracellular Ca2+.6,25 The increase in Ca2+ may be due to influx of Ca2+ from the extracellular fluid15 or release of Ca2+ from intracellular stores such as mitochondria.1,8,18 Whether Ca2+ utilized in transmitter release is liberated from organelles other than mitochondria is uncertain. Smooth endoplasmic reticulum is known to release Ca2+, e.g., on activation by inositol trisphosphate or cyclic adenosine diphosphate-ribose,2 so the possibility exists that Ca2+ from this source may be involved in the events leading to exocytosis. We examined this hypothesis by testing whether inositol trisphosphate and cyclic adenosine diphosphate-ribose modified transmitter release. We used liposomes to deliver these agents into the cytoplasmic compartment and binomial analysis to determine their effects on the quantal components of transmitter release. Administration of inositol trisphosphate (10-4M) caused a rapid, 25% increase in the number of quanta released. This was due to an increase in the number of functional release sites, as the other quantal parameters were unaffected. The effect was reversed with 40min of wash. Virtually identical results were obtained with cyclic adenosine diphosphate-ribose (10-4M). Inositol trisphosphate caused a 10% increase in quantal size, whereas cyclic adenosine diphosphate-ribose had no effect. The results suggest that quantal transmitter release can be increased by Ca2+ released from smooth endoplasmic reticulum upon stimulation by inositol trisphosphate or cyclic adenosine diphosphate-ribose. This may involve priming of synaptic vesicles at the release sites or mobilization of vesicles to the active zone. Inositol trisphosphate may have an additional action to increase the content of transmitter within the vesicles. These findings raise the possibility of a role of endogenous inositol phosphate and smooth endoplasmic reticulum in the regulation of cytoplasmic Ca2+ and transmitter release.

This study examined the precision of central fiber growth in a subpopulation of dorsal root ganglion neurons in developing mouse spinal cord. Immunohistochemical techniques using a monospecific, polyclonal antiserum to mouse adenosine deaminase (ADA) were utilized to label a population of primary sensory afferents that have been found to exclusively innervate laminae I and II of the dorsal horn in adult mice. Initial growth of ADA-immunoreactive (ADA-IR) primary afferents occurred very early in development, embryonic day 10 (E10), a time coincident with the earliest settling time of dorsal root ganglion neurons. Adenosine deaminase immunoreactive primary afferents were observed throughout the cross-sectional area of the primordial dorsal funiculus (DF) as early as E10. Immunostained fibers remained quiescent in the DF during its growth and separation into the tract of Lissauer and dorsal column pathway. By E15, the two pathways had formed and ADA-IR fibers were observed exclusively in the tract of Lissauer. This segregation of fibers remained throughout development and reflected the adult pattern. Growth was reinitiated at E16 when the fibers advanced into the dorsal horn and proceeded directly to laminae I and II mimicking their adult distribution. Exuberant fiber growth was not detected throughout their development. These results strongly suggest that ADA-IR fibers exhibit precise fiber guidance to a preferred pathway, the tract of Lissauer, and accurate laminar innervation of the dorsal horn.

This thesis examines the hypothesis that human erythrocyte net sugar transport is the sum of two serial processes: sugar translocation followed by interaction of newly imported sugar with an intracellular binding complex from which sugar dissociates into the bulk cytosol. This hypothesis suggests that steady-state transport measurements in the human erythrocyte do not accurately reflect the intrinsic catalytic features of the glucose transporter and unless correctly interpreted, may lead to apparent inconsistencies in the operational behavior of the human erythrocyte sugar transport system. Our results support this proposal by demonstrating that although sugar transport measurements in human red blood cells suggest that transport is catalytically asymmetric, ligand binding measurements indicate that transport must be symmetric. In order to examine the serial compartments hypothesis, we set out to determine the following: 1) identify the component(s) of the proposed sugar binding complex, 2) determine whether cytosolic ATP levels and transporter quaternary structure affect sugar binding to the sugar binding complex, and 3) determine whether the sugar binding site(s) are located within or outside the cell. We present findings which support the hypothesis that the sugar binding complex is in fact the sugar transport protein, GLUT1. The number of sugar binding sites and the release of sugar from the GLUT1 complex are regulated by ATP and by GLUT1 quaternary structure. The sugar binding sites are located on a cytoplasmic domain of the GLUT1 complex. We show how these observations can account for the apparent complexity of erythrocyte sugar transport and its regulation by ATP.

For nearly five decades, the simple eukaryote Saccharomyces cerevisiae has been used as a model for understanding the eukaryotic cell cycle. One vein of this research has focused on understanding how chromosome structure is regulated in relation to the cell cycle. This work characterizes a new mechanism that modulates the chromatin organizing condensin complex, in hopes of furthering the understanding of chromosome structure regulation in eukaryotes. During mitosis, chromosomes are condensed to facilitate their segregation through a process mediated by the condensin complex. Upon interphase onset, condensation is reversed, allowing for efficient transcription and replication of chromosomes. This work demonstrates that Ycg1, the Cap-G subunit of budding yeast condensin, is cell-cycle regulated with levels peaking in mitosis and decreasing as cells enter G1 phase. The cyclical expression of Ycg1 is unique amongst condensin subunits, and is established by a combination of cell cycle-regulated transcription and constitutive proteasomal degradation. Interestingly, when cyclical expression of Ycg1 is disrupted, condensin formation and chromosome association increases, and cells exhibit a delay in cell-cycle entry. These results demonstrate that Ycg1 levels limit condensin function, and suggest that regulating the expression of an individual condensin subunit helps to coordinate chromosome conformation with the cell cycle. These data, along with recent corroborating results in Drosophila melanogaster suggest that condensin regulation through limiting the expression of a single condensin subunit may be broadly conserved amongst eukaryotes.

Thesis advisor: Charles Hoffman / In both mammals and fission yeast, control of cAMP levels is maintained by adenylyl cyclases (ACs), which synthesize cyclic nucleotide, and by cyclic nucleotide phosphodiesterases (PDEs), which are responsible for its degradation. AC activity is regulated by G proteins, which respond to signals from G protein-coupled receptors (GPCRs) that detect extracellular signaling factors such as hormones. cAMP is a second messenger that has several effectors, with protein kinase A (PKA) being a primary target of activation that phosphorylates several downstream targets and results in modulation of pathways such as cell growth and gluconeogenesis. Aberrant cAMP regulation has been linked to several human disease states, such as McCune-Albright Syndrome, which is the result of elevated cAMP levels. Whereas the targeting of PDEs with drugs and selective inhibitors has been very successful, the AC-inhibiting compounds identified to date are unfavorable for clinical use. Inhibitors may not necessarily bind to and inhibit a given AC directly but instead act on a regulatory pathway such as calmodulin signaling. Theoretically, they also may bind to the G protein, interfere with the AC-G protein stimulatory complex, or regulate a factor of AC transcription. Since more than one AC species is expressed in many human cell types, it is difficult to selectively reduce cAMP levels. Therefore, for an AC inhibitor to be favored as a candidate for drug development, it is likely that the compound should directly bind to and inhibit the AC. This thesis describes my studies on a scaffold of 41 structurally related BCAC compounds, called the BCAC51 scaffold, that was identified in a high-throughput screen (HTS) with Schizosaccharomyces pombe strains transformed with GNAS and either mammalian AC4 or AC7. I carried out a series of experiments to examine whether the compounds bind to and inhibit mammalian ACs directly. The most active compounds were further characterized for potency and specificity against a panel of ACs. Several compounds significantly reduced cAMP production, but it could not be determined if the compounds directly or indirectly altered AC activity. I also cloned and constructed strains expressing the human wild-type AC5 gene and the AC5 R418W mutant, which has shown an increased sensitivity to GNAS. cAMP assays on these strains using various BCAC compounds showed that while most compounds had similar effects on both forms of AC5, BCAC62 was significantly more effective on the wild-type enzyme than on the mutant AC5, although the reason for this is unclear. To test whether the compounds could reduce AC activity in the absence of GNAS (basal activity), a flow cytometry study was carried out using a PKA-repressed GFP reporter. Results suggested that BCAC compounds do reduce basal-AC activity and therefore do not act by binding to and inhibiting GNAS, by interfering with the AC-GNAS stimulatory complex, nor by stimulating PDE. Finally, I developed a molecular genetic screen for mutant alleles of an AC gene that confer compound-resistance. One cycle of the screen is near completion, and the screen provides a foundation for future examination of compound-resistant AC candidates. The results presented in this thesis serve as a basis for further research into members of the BCAC51 compound series being putative direct inhibitors of mammalian ACs. / Thesis (BS) — Boston College, 2022. / Submitted to: Boston College. College of Arts and Sciences. / Discipline: Scholar of the College. / Discipline: Biology.

A novel method for the immobilization of ribonucleosides to polysaccharides, namely to agarose, is presented, and the immobilized nucleosides are used for the purification of nucleoside-converting enzymes, such as adenosine deaminase, guanase OMP-decarboxylase and xanthine oxidase.

This study investigated if exogenous adenosine (ADO) improves recovery of cardiac function during repetfusion (RPF) after global ischemia (ISC), and if lidocaine is required for. ADO-mediated cardioprotection during reperfusion. Isolated rabbit hearts, retrogradely perfused with erythrocyte-enriched Krebs-Henseleit buffer at constant left ventricular (LV) volume and physiologic flow rates, were subjected to 20 min. of global no-flow ischemia, and reperfused at the same rate as before ischemia. Hearts received one of the following treatments: 1) control (CON; no drug treatment), 2) adenosine (ADO; 200J.1M before and after ISC), or 3) adenosine+lidocaine (NL; 200 JlM ADO before and after ISC, 1 J.Lg/ml/min LIDO during first 20 min. of RPF). Myocardial function (e.g., using developed LV pressure, DP) declined as expected during no-flow ischemia and gradually returned during reperfusion. Functional recovery in ADO and NL groups were significantly improved from CON during early RPF (p<0.05 at 2 min RPF), but not at later RPF times(> 10 min). Differences did not exist between ADO and NL groups at any RPF time except at 10 min. RPF. Additionally, myocardial ATP content was measured before ischemia, after ischemia, and after 10 and 30 min of reperfusion. ATP content decreased significantly during ischemia; ADO hearts showed a increased repletion (85% of pre-ischemia level) of ATP at 30 min. of reperfusionas compared to CON (60%). These data suggest that ADO alone improves cardiac functional recovery during early repetfusion; LIDO does not appear to be required for ADO-mediated cardioprotection. ADO and LIDO do not improve cardiac function, however, ADO appears to improve myocardial ATP repletion at later RPF times in this blood-perfused rabbit model of global myocardial ISC/RPF.